Jane Street’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-116,221
| Closed | -$4.47M | – | 9715 |
|
|
2023
Q2 | $4.47M | Buy |
116,221
+80,272
| +223% | +$2.06M | ﹤0.01% | 2913 |
|
|
2023
Q1 | $832K | Buy |
+35,949
| New | +$857K | ﹤0.01% | 5362 |
|
|
2022
Q4 | – | Sell |
-15,193
| Closed | -$299K | – | 10495 |
|
|
2022
Q3 | $299K | Sell |
15,193
-505
| -3% | -$10.1K | ﹤0.01% | 7601 |
|
|
2022
Q2 | $275K | Buy |
+15,698
| New | +$246K | ﹤0.01% | 7755 |
|
|
2020
Q3 | – | Sell |
-7,923
| Closed | -$91K | – | 8175 |
|
|
2020
Q2 | $91K | Buy |
+7,923
| New | +$109K | ﹤0.01% | 6739 |
|
|
2020
Q1 | – | Sell |
-2,841
| Closed | -$17K | – | 6182 |
|
|
2019
Q4 | $17K | Buy |
+2,841
| New | +$15.4K | ﹤0.01% | 4958 |
|
|
2019
Q3 | – | Sell |
-7,247
| Closed | -$56K | – | 5952 |
|
|
2019
Q2 | $56K | Buy |
+7,247
| New | +$110K | ﹤0.01% | 4940 |
|
|
2019
Q1 | – | Sell |
-4,505
| Closed | -$59K | – | 5827 |
|
|
2018
Q4 | $59K | Buy |
+4,505
| New | +$90K | ﹤0.01% | 4709 |
|
|
2018
Q2 | – | Sell |
-2,031
| Closed | -$94K | – | 5782 |
|
|
2018
Q1 | $94K | Buy |
+2,031
| New | +$74.3K | ﹤0.01% | 4614 |
|
Jane Street's KDNY Position: Q3 2023 in Review
Jane Street sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 116,221 shares — an estimated $4.47M sold.
Jane Street first reported a position in KDNY in Q1 2018 and held it in 9 quarters. The position peaked at $4.47M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Jane Street reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Jane Street sold 116,221 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $4.47M.
- Jane Street first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2018 and held it in 9 quarters.
- Jane Street's Chinook Therapeutics, Inc. Common Stock position peaked at $4.47M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Jane Street's 13F filing for Q3 2023, filed 15 Nov 2023.